

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: <http://www.jmir.org/2011/4/e126/>



doi: 10.2196/jmir.1923

PMID: 22209829

\*必填

Your name \*

First Last

Ting Liu

Primary Affiliation (short), City, Country \*

University of Toronto, Toronto, Canada

Sun Yat-sen University, Guangzhou, China

Your e-mail address \*

[abc@gmail.com](mailto:abc@gmail.com)

1136070817@qq.com

Title of your manuscript \*

Provide the (draft) title of your manuscript.

Effects of App-based Transitional Care on Self-efficacy and Quality of Life of Patients with Spinal Cord Injury in China: Randomized Controlled Trial

Name of your App/Software/Intervention \*

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Together



**Evaluated Version (if any)**

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

您的回答

**Language(s) \***

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Chinese

**URL of your Intervention Website or App**

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

您的回答

**URL of an image/screenshot (optional)**

您的回答

**Accessibility \***

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- 其他:



### Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

spinal cord injury

### Primary Outcomes measured in trial \*

comma-separated list of primary outcomes reported in the trial

self-efficacy, quality of life

### Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

您的回答

### Recommended "Dose" \*

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- 其他: The multidisciplinary team gave the patients with spinal cord injury five



Approx. Percentage of Users (starters) still using the app as recommended after 3 months \*

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- 其他:

Overall, was the app/intervention effective? \*

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- 其他:



**Article Preparation Status/Stage \***

At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- 其他:

**Journal \***

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- 其他:



Is this a full powered effectiveness trial or a pilot/feasibility trial? \*

Pilot/feasibility

Fully powered

Manuscript tracking number \*

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

no ms number (yet) / not (yet) submitted to / published in JMIR

其他:

## TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? \*

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

yes

其他:



**1a-i) Identify the mode of delivery in the title**

Identify the mode of delivery. Preferably use “web-based” and/or “mobile” and/or “electronic game” in the title. Avoid ambiguous terms like “online”, “virtual”, “interactive”. Use “Internet-based” only if Intervention includes non-web-based Internet components (e.g. email), use “computer-based” or “electronic” only if offline products are used. Use “virtual” only in the context of “virtual reality” (3-D worlds). Use “online” only in the context of “online support groups”. Complement or substitute product names with broader terms for the class of products (such as “mobile” or “smart phone” instead of “iphone”), especially if the application runs on different platforms.

1      2      3      4      5

subitem not at all important                        essential

清除所选内容

**Does your paper address subitem 1a-i? \***

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, app-based.

**1a-ii) Non-web-based components or important co-interventions in title**

Mention non-web-based components or important co-interventions in title, if any (e.g., “with telephone support”).

1      2      3      4      5

subitem not at all important                        essential

**Does your paper address subitem 1a-ii?**

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答





1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes")  
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1      2      3      4      5

subitem not at all important                        essential

清除所选内容

Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

for patients with spinal cord injury

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1      2      3      4      5

subitem not at all important                        essential

清除所选内容



Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, background, methods, discussion, and conclusions.

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

|                              |                       |                       |                       |                       |                                  |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                                |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | essential |

清除所选内容

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.



### 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1            2            3            4            5

subitem not at all important                        essential

### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1            2            3            4            5

subitem not at all important                        essential

### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

## INTRODUCTION

### 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

|                              |                       |                       |                       |                       |                                  |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                                |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | essential |

清除所选内容



Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, comparing the effectiveness of two interventions on outcome indicators.

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

|                              |                       |                       |                       |                       |                                  |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                                |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | essential |

清除所选内容



**Does your paper address subitem 2a-ii? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "In China, most newly injured patients with SCI live at home after acute treatment and sub-acute rehabilitation [9]. They urgently require professional medical support and rehabilitation services in communities. However, there is a gap between the health needs of patients with SCI and the existing developing community care system in China. The complexity of SCI means there are more professional requirements for the community medical care. The present community medical resources across China remain imbalanced. Many communities are unable to meet the needs of patients with SCI based on the competency of health professionals and basic community medical facilities [10]. Some well-equipped comprehensive hospitals and rehabilitation centers attempted to fill the gap through transitional care, which extended professional medical care to the families of patients with SCI. The most common formats are home visits, telephone follow-ups, and outpatient services. However, some limitations continue to exist in these approaches, such as the small number of beneficiaries because of distance and insurance [11,12] and inconvenience for patients with motor disabilities receiving outpatient service [13]. With the development of the Internet and prevalence of mobile terminals, such as intelligent cell phones and tablets, mobile health is playing a more important role in the Chinese medical service. Mobile application (app) is a form of mobile health, which is installed on mobile electronic devices with a variety of functions assisting in diagnosis, tele-health-education, and follow-up [14]. Nowadays, apps are widely applied in the transitional care of patients with chronic disease, postoperative patients, and puerperium women. Numerous studies have demonstrated that app-based transitional care could enhance self-efficacy [15-17], prevent complications [18,19], improve QOL [20], and reduce readmissions [21] of patients."

**2b) In INTRODUCTION: Specific objectives or hypotheses**

Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The aim of this research was to test the effects of the app-based transitional care on self-efficacy and QOL of patients with SCI through a randomized controlled trial (RCT).

## METHODS

**3a) Description of trial design (such as parallel, factorial) including allocation ratio**

Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The participants were allocated into 2 groups on a ratio of 1:1.

**3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons**

Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes to methods.



### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The inclusion criteria were: (1) diagnosed with complete or incomplete SCI according to the International Standards for the Neurological Classification of SCI of the American Spinal Injury Association, 2016 [36], and confirmed by computed tomography/magnetic resonance imaging (either traumatic or nontraumatic); (2) onset of SCI within the past 2 years; (3) being alert and conscious, and capable of daily verbal communication; (4) aged >8 years; (5) living at home following discharge; (6) availability of mobile terminals and Internet access at home; and (7) familiarity with the usage of mobile terminals."





#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

|                              |                       |                       |                       |                                  |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                                | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | <input type="radio"/> | essential |

清除所选内容

#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Participants were recruited by trained nurses face-to-face in a comprehensive hospital and three rehabilitation hospitals in Guangzhou, Chengdu, and Shiyan in China."



#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

#### 4b) Settings and locations where the data were collected

##### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "This research was a multicenter and assessor-blinded RCT. It was implemented in four research centers, which included one rehabilitation department in a comprehensive hospital and three rehabilitation hospitals in Guangzhou, Chengdu, and Shiyan in China."



#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

|                              | 1                     | 2                     | 3                     | 4                     | 5                                |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------|
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | essential |

清除所选内容

#### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The outcome measures were collected by researchers at baseline, 12 weeks and 24 weeks following discharge by sending online survey links to the cell phones of patients with spinal cord injury."

#### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



## 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

### 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

1      2      3      4      5

subitem not at all important                        essential

### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1      2      3      4      5

subitem not at all important                        essential

### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



### 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, [webcitation.org](http://webcitation.org), and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1      2      3      4      5

subitem not at all important                        essential

清除所选内容

### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The patients or medical staff downloaded the app by scanning the QR code. A verification system was set in the app and only patients in the study group could pass the identity verification and use the patient-terminal of the app."

### 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], "whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

1      2      3      4      5

subitem not at all important                        essential

清除所选内容



### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The app Together was developed based on the International Classification of Functioning, Disability and Health (ICF), which offered a platform for health professionals to provide follow-up care for patients with SCI at home in China. The development process included four steps [31]: (1) An ICF set for the transitional care outcome indicators of patients with SCI in China was developed in the preliminary studies [31,32]. ICF is a unified and standard terminology system for multidisciplinary use. It provides a comprehensive perspective in describing one's functioning and the interdisciplinary focus rendered it more suitable for multidisciplinary teamwork [33]. (2) Considering the feasibility of clinical practice, the outcome indicators suitable for the SCI follow-up (32 for big follow-up and 12 for small follow-up) (Table 1) were selected from the ICF set above by an expert panel consisting of two rehabilitation physicians and three nursing specialists in SCI. The small follow-ups were more frequently performed at 2, 4, 6, and 8 weeks following discharge, while the big follow-up was only conducted at 12 weeks following discharge. (3) For each indicator, the operational measuring method was set based on the literature review and existing measurements by the expert panel [34]. The app can automatically transform the routine clinical assessments to the unified ICF qualifiers ("0" no problem; "1" mild problem; "2" moderate problem; "3" serious problem; "4" complete problem; and "9" not applicable) for better understanding among the multidisciplinary team. Moreover, a standardized health education program was developed by the expert panel based on the KnowledgeAttitude-Practice theory [35]."

### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |





### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

|                              |                       |                       |                       |                                  |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                                | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | <input type="radio"/> | essential |

清除所选内容



Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The app would automatically remind the follow-up nurse of the patients that had to be contacted within one week prior to the end of the follow-up."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1      2      3      4      5

subitem not at all important                        essential

清除所选内容

Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Firstly, face-to-face training for the follow-up team members of each research center was conducted simultaneously. The training lasted 4 h and consisted of an introductory lecture on the study and app, as well as a workshop on the operation of the app. All members participated in a qualification test after training, with a minimum requirement score of  $\geq 80/100$ ."

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed



Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The outcome measures were collected by researchers at baseline (prior to discharge), 12 weeks following discharge and 24 weeks following discharge by sending online survey links to the cell phones of patients."

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

您的回答

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |



Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

您的回答

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

您的回答

6b) Any changes to trial outcomes after the trial commenced, with reasons



**Does your paper address CONSORT subitem 6b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "We found that patients in the study group who received app-based transitional care had better levels of self-efficacy than those in the control group. However, there was no significant statistical difference in QOL between the two groups.

Our findings indicated that app-based transitional care was effective in enhancing the self-efficacy of patients with SCI. This is consistent with the results of studies involving other populations, such as puerperium women [47], gestational diabetes patients [48], stoma patients [49], etc. The study conducted by MacGillivray et al. [50] also revealed that the mobile app could enhance the confidence of patients with SCI in bowel self-management. The study showed that reinforcing the health-related knowledge of patients can enhance their self-efficacy and self-management behaviors [51]. In our study, the follow-up indicators were extracted from the ICF components, body function, body structure, activities and participation, and contextual factors, which covered the most important issues faced by home-dwelling patients with SCI. These issues included physiological and psychological functional disorders, complications, activities of daily living, and social participation. According to the assessment results of each indicator, standardized health education was provided to patients with SCI, focusing on their knowledge, attitudes, and practice. The delivery and reinforcement of the health information from the medical staff to patients with SCI may be the main reason for the promotion of self-efficacy in patients. Moreover, the app-based transitional care extends the social support from the professional medical staff to patients. It was demonstrated that higher levels of social support are linked to higher levels of self-efficacy [52]. Compared with the control group, the social support provided to patients and caregivers in the study group by a multidisciplinary team was more diverse. Additionally, the abilities of caregivers on caring for patients were also assessed and received interventions in this study. This approach was also valuable for establishing an effective social support system for the patients.

Although we observed that the study group exhibited a greater improvement in QOL total scores than the control group, there were no significant differences observed between the two groups. The results were also consistent with those of the study conducted by Kryger et al. [53], which also examined the effect of an app on patient QOL. Among other tele-interventions to patients with SCI, Shem et al. [54] used FaceTime, a videotelephony app installed on an iPad (Apple Inc., Cupertino, California, USA), to provide a telemedicine program and did not significantly improve the QOL of patients with SCI at 6 months following discharge from the



hospital. It is established that the effects of SCI on patients can influence their physiological health, mental health, and social participation in the long term [55]. Therefore, the QOL of patients with SCI was not easily altered. QOL is a multidimensional concept, composed of one's state of the physical, psychological, and social domains [56]. For the physical aspect, the disabilities were manifested with paraplegia or tetraplegia and seriously affected the functioning and daily activities of patients. For the psychological aspect, patients with SCI often exhibit negative reactions, such as anxiety and depression due to the accidents, disabilities, pain, etc., which greatly affect the subjective feelings of patients regarding life [57]. For the social participation, some studies have shown that significant barriers to social participation exist for patients with SCI due to environmental constraints, the attitudes of others, and family economic status [58]. Therefore, improving the QOL of patients with SCI requires patients, families, health professionals, and even the whole society to provide long-term, integrated support covering all aspects of their physical, mental, and social domains. Notably, the QOL total score and PCS score of the study group showed a better trend than those of the control group. Fan [59] conducted an RCT and found that the QOL of patients with SCI at 12 months following discharge was improved. A longer observation period may provide more valuable information regarding the effects of app-based transitional care on the QOL of patients with SCI."

### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

#### 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |



### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 7b) When applicable, explanation of any interim analyses and stopping guidelines

### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.

### 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The randomization was performed using the software Research Randomizer [37]. This software generated a random number list for each center with two numbers in the list ('1' and '2'), which referred to the study group and control group, respectively. According to the discharge sequence and corresponding randomized number, the recruited patients were randomly assigned to the study group and control group, respectively. The unused numbers would be discarded after completion of the study."



**8b) Type of randomisation; details of any restriction (such as blocking and block size)**

Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Eligible patients were recruited prior to discharge and randomly assigned to the study or control group according to their sequence of discharge on a 1:1 ratio.

**9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned**

Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.

**10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions**

Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The researchers in our research team generated the random allocation sequence by the software Research Randomizer. The trained nurses enrolled participants, and assigned participants to interventions.





### 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

|                              |                       |                       |                       |                                  |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                                | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | <input type="radio"/> | essential |

清除所选内容

#### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is an assessor-blinded RCT. The assessor sent the links of the questionnaire online to all the participants in the study, and they didn't know which group they were belonged to.

#### 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |



**Does your paper address subitem 11a-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

**11b) If relevant, description of the similarity of interventions**

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

**Does your paper address CONSORT subitem 11b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.

**12a) Statistical methods used to compare groups for primary and secondary outcomes**

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

**Does your paper address CONSORT subitem 12a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Differences between the two groups were tested by repeated-measure analysis of variance and simple effect analysis.



**12a-i) Imputation techniques to deal with attrition / missing values**

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

**Does your paper address subitem 12a-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.

**12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses****Does your paper address CONSORT subitem 12b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The normality of the outcome indicators was tested and Cox-box transformation was used to transform non-normal distribution data into normal distribution data. Repeated-measure analysis of variance was used to analyze the main effects of time, group, and time\*group interaction on the MSES and SF-36 scores. In the presence of an interaction effect, simple effect analysis was further performed. P-values  $\leq 0.05$  denoted statistically significant differences."

**X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)**

### X26-i) Comment on ethics committee approval

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



**X26-iii) Safety and security procedures**

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

**Does your paper address subitem X26-iii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

**RESULTS****13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome**

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

**Does your paper address CONSORT subitem 13a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Patients with SCI (n=108) were assessed for eligibility, and 102 patients meeting the inclusion criteria were randomly allocated to two groups. Eventually, only 98 patients completed the study (49 patients per group). In the study group, two cases were lost to follow-up at week 24; the reasons were suicide and disconnection, respectively. In the control group, two cases were lost to follow-up (due to disconnection) at weeks 12 and 24, respectively. The overall effective follow-up rate in this study was 96.08% and the attrition rate was 3.92%."



### 13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "In the study group, two cases were lost to follow-up at week 24; the reasons were suicide and disconnection, respectively. In the control group, two cases were lost to follow-up (due to disconnection) at weeks 12 and 24, respectively."

#### 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 14a) Dates defining the periods of recruitment and follow-up



**Does your paper address CONSORT subitem 14a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Participants were recruited from May 2018 to December 2019. The whole intervention was performed from May 2018 to April 2020."

**14a-i) Indicate if critical "secular events" fell into the study period**

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

1            2            3            4            5

subitem not at all important                        essential

**Does your paper address subitem 14a-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

**14b) Why the trial ended or was stopped (early)****Does your paper address CONSORT subitem 14b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not application. Target enrollment met.



### 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.

#### 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

1      2      3      4      5

subitem not at all important                        essential

清除所选内容

#### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.

### 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups





### 16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

1      2      3      4      5

subitem not at all important                        essential

清除所选内容

### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.

### 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1      2      3      4      5

subitem not at all important                        essential

### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



**17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)**

Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.

**17a-i) Presentation of process outcomes such as metrics of use and intensity of use**

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

1      2      3      4      5

subitem not at all important                        essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

**17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended**



**Does your paper address CONSORT subitem 17b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No effect size was recommended.

**18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory**

**Does your paper address CONSORT subitem 18? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Other statistical analysis were performed.

**18-i) Subgroup analysis of comparing only users**

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

**Does your paper address subitem 18-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



## 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

### Does your paper address CONSORT subitem 19? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.

### 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |



### Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

## DISCUSSION

### 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

subitem not at all important      1      2      3      4      5      essential

                      

清除所选内容

### Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "We found that patients in the study group who received app-based transitional care had better levels of self-efficacy than those in the control group. However, there was no significant statistical difference in QOL between the two groups."



### 22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

#### 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

|                              |                       |                       |                       |                       |                                  |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                                |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input checked="" type="radio"/> | essential |

清除所选内容



### Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The study had some limitations. Firstly, the sample size of the study was small. Owing to the low incidence of SCI and the limitation on the duration of disease (within 2 years), only 98 eligible patients recruited from four research centers completed the follow-up. Secondly, the observation period was limited. We followed discharged patients with SCI up to only 24 weeks. Thus, the long-term effects of app-based transitional care should be further investigated."

### 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

#### 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
| subitem not at all important | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | essential |

### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答



### 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

1      2      3      4      5

subitem not at all important                        essential

### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### OTHER INFORMATION

### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Chinese Clinical Trial Registry ChiCTR-IPR-17012317"

### 24) Where the full trial protocol can be accessed, if available





**Does your paper address CONSORT subitem 24? \***

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, [www.chictr.org.cn/index.aspx](http://www.chictr.org.cn/index.aspx)

**25) Sources of funding and other support (such as supply of drugs), role of funders****Does your paper address CONSORT subitem 25? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "This study was supported by the National Natural Science Foundation of China (71603293) and the Fundamental Research Funds for the Central Universities (20ykpy88)."

**X27) Conflicts of Interest (not a CONSORT item)****X27-i) State the relation of the study team towards the system being evaluated**

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

|                              |                       |                       |                       |                       |                       |           |
|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
|                              | 1                     | 2                     | 3                     | 4                     | 5                     |           |
|                              | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |           |
| subitem not at all important |                       |                       |                       |                       |                       | essential |



### Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

### About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? \*

- yes, major changes
- yes, minor changes
- no

What were the most important changes you made as a result of using this checklist?

您的回答

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript \*

3 hours.



As a result of using this checklist, do you think your manuscript has improved? \*

- yes
- no
- 其他:

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes
- no
- 其他:

Any other comments or questions on CONSORT EHEALTH

您的回答

**STOP - Save this form as PDF before you click submit**

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

**Final step: Click submit !**

Click submit so we have your answers in our database!

提交

切勿通过 Google 表单提交密码。



此内容不是由 Google 所创建，Google 不对其作任何担保。 [举报滥用行为](#) - [服务条款](#) - [隐私权政策](#)

# Google 表单

